Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin and heart failure.

P Nambi1, M Clozel, G Feuerstein

  • 1Cardiovascular Diseases Research, DuPont Pharmaceuticals Company, Wilmington, DE, USA.

Heart Failure Reviews
|July 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of thyrotropin-releasing hormone on lipoxygenase-induced hypotension in the unanesthetized Guinea pig.

Pharmaceutical research·2013
Same author

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.

British journal of cancer·2011
Same author

Apoptosis and congestive heart failure.

Trends in cardiovascular medicine·2011
Same author

Measurements of blood pressure and electrocardiogram in conscious freely moving guineapigs: a model for screening QT interval prolongation effects.

Laboratory animals·2007
Same author

The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat.

Xenobiotica; the fate of foreign compounds in biological systems·2007
Same author

Heart failure--an epidemic of the 21st century? 25th Institut Pasteur Euroconference. 26-27 June 2000, Paris, France.

IDrugs : the investigational drugs journal·2005
Same journal

Mavacamten in adolescent obstructive hypertrophic cardiomyopathy: SCOUTing a way forward.

Heart failure reviews·2026
Same journal

Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.

Heart failure reviews·2026
Same journal

Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.

Heart failure reviews·2026
Same journal

Beyond the right ventricle: left heart involvement in pulmonary arterial hypertension.

Heart failure reviews·2026
Same journal

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same journal

Correction to: Left atrial shunting devices: why, what, how, and… when?

Heart failure reviews·2026
See all related articles

Potent endothelin (ET) receptor antagonists show promise for treating heart failure and pulmonary hypertension. The optimal antagonist type, whether ET(A)-selective or dual ET(A/B) blockade, remains under investigation for heart failure.

Area of Science:

  • Cardiovascular Pharmacology
  • Renal Physiology
  • Endothelin Receptor Antagonism

Background:

  • Endothelin-1 (ET-1) plays a significant role in cardiovascular and renal diseases.
  • Orally active nonpeptide endothelin (ET) receptor antagonists are available for research.
  • Preclinical models demonstrate ET-1's involvement in hypertension, renal failure, heart failure, and pulmonary hypertension.

Purpose of the Study:

  • To review the pathophysiological role of ET-1 in various disease models.
  • To evaluate the clinical benefits of ET-1 receptor antagonists in humans.
  • To address the unresolved question of whether ET(A)-selective or ET(A/B) antagonists are more suitable for congestive heart failure (CHF) treatment.

Main Methods:

  • Review of preclinical data on ET-1 receptor antagonists.

Related Experiment Videos

  • Analysis of clinical trial data regarding hemodynamic effects.
  • Examination of the distinct roles of ET(A) and ET(B) receptors in physiological processes.

    • Main Results:

    • ET-1 receptor antagonists demonstrate beneficial effects on hemodynamics in CHF and pulmonary hypertension.
    • Clinical trials show equivalent hemodynamic effects between mixed ET receptor antagonists and ET(A) selective antagonists.
    • The specific roles of ET(B) receptors in kidney function and vasodilation require further consideration.

    Conclusions:

    • ET-1 receptor antagonists offer therapeutic potential for cardiovascular and renal conditions.
    • Preserving ET(B)-mediated responses in the kidney and pulmonary endothelium may be beneficial in heart failure and chronic renal disease.
    • Further research is needed to determine the optimal ET receptor antagonist strategy for CHF treatment, balancing potential benefits and risks associated with ET(B) receptor blockade.